Basilea announces data presentations at ESMO Virtual Congress 2020

Basel, Switzerland, July 28, 2020

Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that three abstracts featuring preclinical and clinical data on its fibroblast growth factor receptor (FGFR) kinase inhibitor derazantinib and its tumor checkpoint controller lisavanbulin are going to be presented as e-posters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which is taking place from 19-21 September, 2020.

Dr. Marc Engelhardt, Chief Medical Officer, said: “The preclinical derazantinib data may provide an explanation for differences in reported adverse event profiles between various FGFR kinase inhibitors. Furthermore, derazantinib shows promising efficacy in patient-derived tumor models with gene aberrations in FGFR1-3. The data which will be presented at ESMO are part of our broad preclinical and clinical program focused on generating further scientific evidence for the differentiation of derazantinib, in order to explore its full therapeutic potential in FGFR-driven tumors.”

He continued: “We are also pleased that the full data from the phase 1 study with oral lisavanbulin in patients with recurrent glioblastoma will be presented at ESMO. As previously reported, we observed clinical benefit in a subset of patients in the study. In particular, one patient shows an exceptional long-lasting response and the brain tumor tissue of this patient is strongly positive for EB1, a potential response-predictive biomarker. Based on the results from this and other clinical and preclinical studies, we are currently preparing the start of a biomarker-driven phase 2 study in patients with recurrent glioblastoma and subsequently potential additional tumor types.”

The following e-posters are scheduled for presentation at ESMO Virtual Congress 2020:
Presentation #	Title
1960P	Differential induction of gene expression may explain differences in reported adverse event profiles between the FGFR-inhibitors derazantinib and erdafitinib: an analysis in safety relevant normal tissues from urothelial cancer (UC) patient-derived mouse xenograft (PDX) models.
	Presenting author: Paul McSheehy
541P	Derazantinib (DZB), an oral Fibroblast Growth Factor Receptor inhibitor (FGFRi), shows promising activity in PDX-tumor models with aberrations in FGFR1-3
	Presenting author: Paul McSheehy
382P	The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: Final results from a phase 1 study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma (GBM)
	Presenting author: Crescens Tiu

For further information, please visit https://www.esmo.org/meetings/esmo-virtual-congress-2020